';

Meta

Log in
Entries RSS
Comments RSS
WordPress.org

Recent Comments

Recent Posts

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment February 5, 2019
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record January 15, 2019

Unknown Feed

Search

Tag Cloud

Agricultural Technology AstraZeneca Bayer Bio-Rad Biopharma Bioproduction Biotech bluebird bio Cancer Immunotherapy Celgene Cell Therapy Chemicals CRO/CMO Diagnostics Drug Development Evolution Global Press Releases Evolution Infographics GE Healthcare Genentech Gene Therapy Genomics & Proteomics GSK Illumina Informatics & Analytics Johnson & Johnson Juno Therapeutics KITE Pharma Life Sciences Lonza Medical Devices Merck Mergers Partnerships & Acquisitions Metagenomics MilliporeSigma Next Generation Sequencing Novartis Pfizer Regenerative Medicine Roche Samsung BioLogics Sanofi Sartorius Stedim Sigma-Aldrich The Future of BioManufacturing Thermo Fisher Scientific

Text

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In in lorem sit amet ligula feugiat vulputate vel vitae quam. Cras posuere imperdiet lorem, in aliquam urn

CategoriesTitle

Evolution Infographics
News & Analysis

ArchivesTitle

Cat tabs

: First
: Second
: Third

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

+44 141 248 2026info@evolution-bio.comNewsletter Sign-UpDownload Our BrochureEvolution Executive Search

Home
Clients & Core Services
News & Analysis
- The Future of BioManufacturing
IPO Tracker

Downstream Processing

The Future of Biomanufacturing: Automated Closed Systems for Cell & Gene Therapy Processes

The Future of Biomanufacturing: Automated Closed Systems for Cell & Gene Therapy Processes

More

Share

The Future of Biomanufacturing: In Silico Modelling

The Future of Biomanufacturing: In Silico Modelling

More

Share

The Future of BioManufacturing: Downstream Processing

The Future of BioManufacturing: Downstream Processing

More

Share

The Future of BioManufacturing

More

Share

Search

THE FUTURE OF BIOMANUFACTURING

Browse By Category

Agricultural Technology Bioinformatics Biopharma Bioproduction Biotech Cancer Immunotherapy Cell Line Engineering Cell Therapy Chemicals CRO/CMO Diagnostics Downstream Processing Drug Development Gene Therapy Genomics & Proteomics Informatics & Analytics Life Sciences Medical Devices Mergers Partnerships & Acquisitions Metagenomics Modular Factories Molecular Pathology Next Generation Sequencing Regenerative Medicine The Future of BioManufacturing

Browse By Company

ACD Bio AstraZeneca Bayer Bio-Rad bluebird bio Celgene Evolution Global Press Releases GE Healthcare Genentech GSK Illumina Johnson & Johnson Juno Therapeutics KITE Pharma Lonza Merck MilliporeSigma Novartis Pfizer Roche Samsung BioLogics Sanofi Sartorius Stedim Sigma-Aldrich Thermo Fisher Scientific

RECENT POSTS

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong

Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

DATA VISUALISATIONS

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

About Us

Evolution Bioscience is a global consultancy firm, specialising in market intelligence, strategy formulation, technology transfer and commercialisation services, covering the full range of Biotechnology sectors.

Get In Touch

+44 141 248 2026

info@evolution-bio.com

Recent Posts

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record

2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong

Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong

BROWSE NEWS BY INDUSTRY

Agricultural Technology Biopharma Bioproduction Biotech Cancer Immunotherapy Cell Therapy Chemicals CRO/CMO Diagnostics Drug Development Gene Therapy Genomics & Proteomics Informatics & Analytics Life Sciences Medical Devices Mergers Partnerships & Acquisitions Metagenomics Next Generation Sequencing Regenerative Medicine The Future of BioManufacturing

BROWSE NEWS BY COMPANY

Bayer Bio-Rad bluebird bio Celgene Evolution Global Press Releases GE Healthcare Genentech GSK Illumina KITE Pharma Lonza Merck MilliporeSigma Novartis Roche Samsung BioLogics Sanofi Sartorius Stedim Sigma-Aldrich Thermo Fisher Scientific

2016 © Evolution Bioscience / Darwin Hutton Partners

Search for: